Case Report
Copyright ©The Author(s) 2024.
World J Hepatol. Feb 27, 2024; 16(2): 286-293
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.286
Table 1 Blood test
Blood testValueUnit
Hematology
WBC59.00× 102/μL
RBC400.00× 104/μL
Hb12.30g/dL
Ht37.30%
PLT13.30× 104/μL
PT (%)81.90%
Serum chemistry
TP9.70g/dL
ALB3.60g/dL
T-Bil1.00mg/dL
AST418.00U/L
ALT366.00U/L
ALP371.00U/L
γ-GT102.00U/L
LD388.00U/L
BUN13.40mg/dL
Cre0.65mg/dL
CRP0.02mg/dL
IgA605.00mg/dL
IgM795.00mg/dL
IgG3481.00mg/dL
ANA80
ASMA640
AMA< 20
HAV-IgMNegative
HEV-IgANegative
HBs-AgNegative
HBs-AbNegative
HBc-AbPositive
HBV-DNA< 2.1Logcopy/mL
HCV-AbPositive
HCV-RNA< 1.2LogIU/mL
CMV-IgMNegative
CMV-IgGPositive
VCA-IgMNegative
VCA-IgGPositive
EBNAPositive
HLADR4
Table 2 Blood test results (antinuclear antibody and antismooth muscle antibody)
Blood test
ANA
ASMA
Before DAAs (SOF/LDV) therapy< 20< 20
After DAAs (SOF/LDV) therapy4020
SVR 1240160
SVR 2480640
Table 3 Four cases of autoimmune hepatitis development following direct antiviral agent treatment
Ref.
Age
Sex
HLA-DR4
Autoimmune disease
Genotype
DAA
Onset
Treatment
Follow up
Matsumoto et al[29], 201881FemaleNegativeNone1 (serotype)EBR/GZR2 monthsPSLImprovement
Covini et al[31], 201872FemaleNAITP1bSOF/LDV2 wkPSLImprovement
Montón et al[30], 202072FemaleNANone1bSOF/LDV3 yrPSLImprovement
Our case80FemalePositiveNone1bSOF/LDV9 monthsPSL + UDCADevelopment of PSC